No Fracture Risk for New Diabetes Drugs in Real-World Study No Fracture Risk for New Diabetes Drugs in Real-World Study
Link between SGLT2 inhibitors for type 2 diabetes and fractures has been controversial. Canagliflozin has an FDA warning about the risk, but some studies have found no link.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 17, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density
[9-10-2015] The U.S. Food and Drug Administration (FDA) has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures and added new information about decreased bone mineral density. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

CREDENCE'Knocks Your Socks Off'; New Analysis Reported at ADA CREDENCE'Knocks Your Socks Off'; New Analysis Reported at ADA
Latest analysis of CREDENCE with SGLT2 inhibitor canagliflozin shows the agent has a cardio- and renal-protective effect in both primary and secondary CV prevention populations.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 17, 2019 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

INVOKANA ® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 11, 2019 Category: Pharmaceuticals Source Type: news

ADA Standards Updated With Renal Guidance Based on CREDENCE ADA Standards Updated With Renal Guidance Based on CREDENCE
New renal management guidance is based on data from the recently reported Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE) trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 4, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

U.S. FDA Grants Priority Review of INVOKANA ® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 22, 2019 Category: Pharmaceuticals Source Type: news

Old Malaria Drug as Good as Blockbuster Type 2 Diabetes Agent Old Malaria Drug as Good as Blockbuster Type 2 Diabetes Agent
When added to metformin and vildagliptin, hydroxychloroquine lowered HbA1c as well as canagliflozin and also reduced weight and inflammation.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 3, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Novel therapies slow CKD progression in patients with diabetes
(ERA-EDTA) The recently published CREDENCE study showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. Canagliflozin was associated with a 34% risk reduction of the renal end point. The SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2019 Category: International Medicine & Public Health Source Type: news

Teprotumumab, Canagliflozin, and Kevin Pho Top AACE Agenda Teprotumumab, Canagliflozin, and Kevin Pho Top AACE Agenda
Graves ' ophthalmopathy, type 2 diabetes treatment, social media matters, and much more to be featured at Los Angeles conference.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 16, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Common Diabetes Drug May Also Help Kidneys, Heart
Those who took Invokana had a 30% lower risk of developing kidney failure, a 30% lower risk of dying from kidney failure or heart disease, the researchers reported. (Source: WebMD Health)
Source: WebMD Health - April 16, 2019 Category: Consumer Health News Source Type: news

Treatment success for diabetic kidney disease
Clinical trial findings inThe New England Journal of Medicine report that canagliflozin can reduce the risk of kidney and cardiac failure in patients with diabetes.iNews (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 16, 2019 Category: Endocrinology Source Type: news

Canagliflozin Seems Effective for Patients With T2DM, Kidney Disease
MONDAY, April 15, 2019 -- Canagliflozin is associated with a reduced risk for renal and cardiovascular events for patients with type 2 diabetes and kidney disease, according to a study published online April 14 in the New England Journal of Medicine... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 15, 2019 Category: Pharmaceuticals Source Type: news

Diabetes Drug'Home Run' Curtailing Kidney Failure Risk Diabetes Drug'Home Run' Curtailing Kidney Failure Risk
Canagliflozin also showed cardiovascular benefits in the CREDENCE multicenter trial, with no imbalance in adverse events, investigators shared here at the nephrology world congress.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 15, 2019 Category: Cardiology Tags: Nephrology News Source Type: news

Common Diabetes Drug Invokana (canagliflozin) May Also Shield Kidneys, Heart
MONDAY, April 15, 2019 -- A common diabetes drug may also greatly reduce the odds for death from kidney failure and heart disease in diabetes patients with kidney disease, a new study finds. The news on Invokana (canagliflozin) is important,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 15, 2019 Category: General Medicine Source Type: news

INVOKANA ® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 15, 2019 Category: Pharmaceuticals Source Type: news